Gerald H Lushington and Anthony C Barnes
For decades, a great deal of public attention has followed the search for cures for cancer, heart disease and viral infections, but the single most expensive, and seemingly intractable, medical challenge in the industrialized world is Alzheimer’s disease [1]. The history of Alzheimer’s clinical trials has been notoriously disappointing [2], but are we truly doomed to continue repeating this futility? In fact, there are grounds for hope. In recent years, in a focal areas distinct from the clinical failures, we have seen fascinating progress on several potentially convergent fronts of that may afford promising new therapeutic opportunities.
